Rep. Gilbert Cisneros Buys Vaxcyte, Inc. Shares
Congressman Gilbert Cisneros purchased shares of Vaxcyte, Inc. valued between $1,001 and $15,000.
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Cisneros (D-CA)
- Status:
- Member — House
- State/District:
- CA-31
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 9, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Vaxcyte, Inc. ($PCVX) | Buy | May 12, 2026 | $1,001 - $15,000 |
Key Points
- Gilbert Cisneros, a member of the House, bought Vaxcyte, Inc. shares valued between $1,001 and $15,000, reported on June 9, 2026.
- Vaxcyte, Inc. shares are trading at $47.46 with a market cap of $6.85 billion and a beta of 1.242.
- Institutional investors like Janus Henderson and FMR LLC have also increased their stakes in Vaxcyte recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 9, 2026, Congressman Gilbert Cisneros disclosed a purchase of Vaxcyte, Inc. shares valued between $1,001 and $15,000. This transaction was reported after the trade, which took place on May 12, 2026. Cisneros, a member of the House of Representatives, showed interest in the biotechnology company that is currently trading at $47.46 per share.
Gilbert Cisneros vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Vaxcyte
In addition to Cisneros's purchase, several institutional investors have made moves with Vaxcyte stock. Janus Henderson Group PLC grew its holdings by 3,188,687 shares, ending with 16,575,875 shares valued at approximately $960.2 million. FMR LLC also increased its position by 2,658,347 shares, bringing its total to 16,492,861 shares worth about $958.4 million. T. Rowe Price Investment Management, Inc. added 829,684 shares, now holding 12,126,017 shares valued at $704.6 million.
Vaxcyte, Inc. Stock Down 17.2%
Vaxcyte, Inc. (NasdaqGS: PCVX) is trading at $47.46, with a market capitalization of $6.85 billion. The company has a forward P/E ratio that is not meaningful as it isn't currently profitable. Its beta, a measure of volatility, stands at 1.242. Over the past year, the stock has ranged from a low of $29.08 to a high of $65.00. The 50-day moving average is $54.48, while the 200-day moving average is $48.67. Vaxcyte maintains a strong financial position with a current ratio of 7.49 and a quick ratio of 7.18.
$PCVX stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Vaxcyte reported its latest earnings on May 6, 2026. The company is still in the clinical stage and has not yet generated revenue. Its earnings per share were negative at -$6.89, reflecting ongoing investment in research and development. Vaxcyte's return on equity is -30.55%, indicating the challenges of funding its innovative vaccine pipeline.
Insider Buying and Selling at Vaxcyte, Inc.
Several insiders have been active in trading Vaxcyte shares. Jim Wassil, the Chief Operating Officer, sold 2,250 shares on June 1, 2026, at an average price of $49.52, as part of a planned sale. Previously, Wassil sold additional shares on May 1 and April 1. Elvia Cowan, SVP of Finance & CAO, also executed trades, selling 3,000 shares on April 7 at $60.00, while buying 3,000 shares at $25.92 on the same day.
Analysts Set New Price Targets
Analysts remain optimistic about Vaxcyte's potential. On February 26, 2026, BTIG maintained a buy rating with a price target of $89. Guggenheim reiterated its buy rating with a target of $116 on February 2, 2026. The consensus among analysts is a strong buy, with a mean price target of $109, based on nine analyst opinions.
About Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology company focused on developing vaccines to prevent bacterial infections. Headquartered in San Carlos, California, the company is led by CEO Grant E. Pickering. Vaxcyte's lead product is VAX-24, a pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease. The company is also developing other vaccine candidates targeting various bacterial pathogens.
Bottom Line
Gilbert Cisneros's purchase of Vaxcyte shares highlights ongoing interest in the company's potential. Vaxcyte is a clinical-stage biotech firm with a promising vaccine pipeline, though it remains unprofitable. Institutional investors and analysts show strong interest, reflecting confidence in Vaxcyte's future prospects. Remember, these trades are disclosed after the fact and may not reflect current positions.
Get Vaxcyte, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PCVX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.